酒精相关肝病的无创诊断与生物标志物
酒精相关肝病(ALD)多数患者在失代偿期才被诊断,肝活检仍为金标准但有创。瞬时弹性成像检测肝硬度对晚期纤维化和肝硬化有优良性能,但解读截断值需考虑天冬氨酸氨基转移酶水平。增强肝纤维化试验和FibroTest诊断晚期纤维化性能相当,可能优于FIB-4和APRI;磁共振技术检测脂肪变性准确可重复但成本高,受控衰减参数联合瞬时弹性成像可能优于常规超声。
要点
- 瞬时弹性成像检测肝硬度对ALD晚期纤维化和肝硬化有优良诊断性能。
- 解读肝硬度截断值时需考虑天冬氨酸氨基转移酶水平。
- 增强肝纤维化试验和FibroTest诊断晚期纤维化性能相当,可能优于FIB-4和APRI。
核心结论
- 无创检测可用于评估ALD肝纤维化和脂肪变性的严重程度,但磁共振技术因可用性低和成本高限制其在常规临床实践中的应用。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 瞬时弹性成像检测肝硬度对ALD晚期纤维化和肝硬化有优良性能,但解读截断值需考虑天冬氨酸氨基转移酶水平。
- 增强肝纤维化试验和FibroTest诊断ALD晚期纤维化性能相当,研究提示优于FIB-4和APRI等其他生物学检测。
- 磁共振波谱和磁共振成像技术检测组织学脂肪变性的敏感性和特异性优于超声,且高度准确可重复。
- 受控衰减参数联合瞬时弹性成像检测脂肪变性可能优于常规超声,并显示可接受的诊断准确性。
- 新的血清生物标志物正在研究中,用于无创诊断更严重形式的ALD和预测患者预后。
临床怎么用
- 原文未据此给出推荐。
局限性
- 磁共振技术可用性低且成本高,限制其在常规临床实践中的应用。
- 新的血清生物标志物尚在研究中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Even though alcohol-related liver disease (ALD) is a major cause of severe liver disease worldwide, most patients with ALD are diagnosed at the decompensation stage. Liver biopsy is still considered the gold standard for establishing a definite diagnosis and assessing the fibrosis stage of ALD, but it is an invasive procedure, associated with significant morbidity. During the last decade, non-invasive tests have been developed to estimate the severity of liver fibrosis and steatosis. Measurement of liver stiffness by transient elastography has become the most commonly used non-invasive parameter to evaluate fibrosis. In ALD, transient elastography has been demonstrated to have an excellent performance to detect advanced fibrosis and cirrhosis. However, aspartate aminotransferase levels must be considered when interpreting liver stiffness cut-offs. Non-invasive biological tests have also been evaluated to assess liver fibrosis in ALD. The commercially available Enhanced Liver Fibrosis test and FibroTest have comparable performance for the diagnosis of advanced fibrosis in ALD, with studies suggesting that they are better than other biological tests (i.e. FIB-4 and APRI). Although ultrasound is still accepted as an initial screen for fatty liver diagnosis, new methods have recently been developed to detect steatosis. Magnetic resonance spectroscopy and magnetic resonance imaging techniques are highly accurate and reproducible, with superior sensitivities and specificities for detecting histological steatosis than ultrasound. However, low availability and high cost limit the use of magnetic resonance techniques in routine clinical practice. More recently, controlled attenuation parameter was developed as a novel tool to non-invasively assess liver steatosis; performed in combination with transient elastography, it was suggested to be superior to regular ultrasound for detecting steatosis and was shown to have acceptable diagnostic accuracy. New serum biomarkers are under investigation to non-invasively diagnose more severe forms of ALD and to predict prognosis of patients.
引用
- Moreno C, Mueller S, Szabo G, et al. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019. PMID: 30658728. doi:10.1016/j.jhep.2018.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。